u/sten_palacios

Nothing on this board is legal advice. Where a notice carries a deadline or a consequence, that is a matter for somebody qualified in your own jurisdiction.

Published reimbursement criteria exist in most member states and are usually available in the national language. They are the authoritative answer to eligibility questions that this board can only guess at.

Yes — reconstitution date on the vial. It is the number you will want and cannot reconstruct.

Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.

Which country, and which country did it ship from?

Yes — a logger in the box turns a fortnight of speculation into a chart.

network and address, checked twice, before anything else

Network fees are set by chain congestion at the time of sending. They are paid to the network, not to the recipient, and they vary by hour as well as by chain.

Not convinced. Cross-trial comparison between two programmes with different populations and designs is not a comparison.

keep the hash, it is the only receipt that exists

Supply notices are issued nationally. A notice in one member state does not imply availability problems in another, even for the same product.

Regional stock changes the question rather than answering it: shorter lanes mean less exposure and fewer variables, which is why the warehouse question is worth asking before ordering in summer.

I would not draw a trend line through that. Two points and a gap is not a series.

Vials and pens carry the same molecule; what differs is fill volume, device tolerance and whether you are doing your own arithmetic. Neither is inherently more accurate.

Came off sema and onto tirz with a two-week gap. The first month was flat and I assumed I had made a mistake. Month two it moved.

You cannot infer potency from a temperature record. The record tells you what happened to the box; only a test tells you what happened to the material.

pack sizes differ, so per-month comparisons need care

Not sure that follows.

Saving this one. It is the clearest statement of the stall problem I have read here.

Powder or already in solution?

pack sizes differ, so per-month comparisons need care

SURMOUNT-1 landed around 21% at 72 weeks on the top arm

The thing nobody warned me about was how much of this is logistics — storing it, remembering it, the same day every week.

Got a request for information and treated it as a seizure for two days before actually reading it. It was neither dramatic nor difficult.

ask which lines are held in regional stock before you order in July

Same experience with the appetite effect being flatter across the week rather than front-loaded.

network and address, checked twice, before anything else

Rate quotes expire because the underlying rate moves. A short expiry is ordinary; urgency about your decision is a separate signal and should be read separately.

Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.

Correction to my own post above — I said 10mg and I have been on 12.5mg since the spring. Same argument, wrong number.

Did you come to this from sema, and if so how long was the gap?

powder at room temperature for a few days is usually a non-event

the value of a log is in month six, not week one

You cannot infer potency from a temperature record. The record tells you what happened to the box; only a test tells you what happened to the material.

Intention-to-treat analyses everybody randomised regardless of what they did afterwards.

Agreed. And the interval, not the point estimate, is what the trial actually established.

Postprandial excursions flattened out first and the fasting number took months to follow. Nobody had told me to expect that order.

Fasting or postprandial?

Nothing on this board is legal advice. Where a notice carries a deadline or a consequence, that is a matter for somebody qualified in your own jurisdiction.

Discharge from a specialist service at goal is a normal end point of that pathway. Whether prescribing continues in primary care afterwards is a local decision and is worth asking about at the start rather than at the end.

Is that intention-to-treat or completers?

Read a press release and the publication three months apart. The hedging in the second one was substantial.